InSyBio has joined the Loyal VC program which includes an initial investment from the Toronto, Canada based international fund and provides InSyBio with access to Loyal VC’s global network of over 400 advisors and experienced entrepreneurs, accelerator leaders, advisors, angels and venture investors.
InSyBio will benefit from active business development support and guidance as well as having access to various valuable resources and services as part of the Loyal VC program.
InSyBio’s CEO Labros Digonis stated: “with the Loyal VC program we shall speed up the completion of our open financing round and accelerate the accomplishment of both our business and technological targets, most important of which are:
The launching and commercialization of the InSyBio Precision Chronic Pain Treatment Tool
To continue improving the InSyBio Suite by incorporating our clients’ feedback and by integrating additional tools in it like Thematic platforms for Cancer, Neurodegenerative Diseases and Nutrition
And eventually to evolve at such a level where the InSyBio suite will be the platform of choice for the discovery of biomarkers from single and multi-omics data.” And finally he added “between Insybio and Loyal VC it surely begins an encouraging win-win situation”
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
About Loyal VC: Loyal VC operates a global startup index fund with over 160 investments across more than 38 countries. The fund is designed to minimize systemic bias inherent in the investment process, unlocking greater returns. The Loyal Startup Index Fund has delivered strong returns since its launch in 2018, thanks to its collaborative, staged investment process, its network of over 400 advisors, and its global relationships with the Founder Institute, the world’s largest pre-seed accelerator, and INSEAD, rated the #1 non-US business school for unicorn founders by Pitchbook. Loyal’s global start-up index fund is inclusive of a diverse, often mission-driven, group of entrepreneurs. To date over 30% of the portfolio have a woman CEO, almost 30% are from emerging markets, and around 80% address one or more of the United Nation’s Sustainable Development Goals (UNSDGs).
In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science LLC and developed a machine learning-based tool for predicting the response of chronic pain patients to 4 different non-opioid pain treatment formulations. This tool is capitalizing on InSyBio’s unique machine learning technology to develop machine learning models that are able to predict various response to treatment metrics (including pain severity and interference scales as well as reduction of total drugs) with an unprecedented accuracy. The accuracy of these models in predicting the changes in the response to treatment metrics exceeded 82% for all metrics in a cohort of more than 600 patients while 98.1% of the participants which were classified as responders to non-opioid treatments presented substantial improvement in all metrics in a follow-up after 3-6 months from baseline.
The Precision Chronic Pain Treatment Tool is a first-of-its-kind tool that is able to stratify chronic pain patients into individuals who will benefit from topical analgesics treatment and select the most suitable non-opioid treatment formulation for them using as input a combination of demographics, clinical characteristics and other responses to a simple questionnaire.
The first version of this tool is available for a free trial usage by clinicians treating Chronic pain patients (get it from here ) offering them the following features:
Evaluation of chronic pain situation of patients through the completion of a user-friendly web form
Monitoring the progress of chronic pain patients over the time (trends, graphical representation of their clinical and demographics characteristics etc.)
Suggesting suitable patients for non-opioid treatments
Suggesting the best performing non-opioid treatment among 4 different formulations.
A simpler version of this tool is available for chronic-pain patients (get it from here) to allow them to identify if a non-opioid treatment is suitable for them and suggest them discussing additional therapeutic options with their physician.
In the next few months this tool will be expanded with additional non-opioid formulations and treatments (such as pain patches), with more specialized versions for specific chronic pain etiologies, such as Osteoarthritis and Rheumatoid Arthritis, and incorporating biomarkers to improve the predictive accuracy of the utilized prognostic models.
Peter Hurwitz, President of Clarity Science states: “Through their predictive analytic and artificial intelligence algorithms, the team at InSyBio has developed a simple and unique tool that will allow patients and clinicians the ability to identify suitable treatments, and more importantly, treatments that will predict the likelihood of response prior to the patient beginning that treatment. Identifying treatments that may generate a positive outcome prior to prescribing is very exciting as it will cut down on unnecessary treatment trials, adverse events and side effects, time for a patient to feel relief, and cost, just to name a few advantages. With so many treatment options available, anything that may help in identifying the best approach upfront will be welcomed by the healthcare community and patients.”
Seferina Mavroudi, Chief Scientific Officer of InSyBio states: “Our tool is based on a Sophisticated, Interpretable Machine Learning approach to provide health care providers with a high accuracy yet trustable and transparent decision aid. Leveraging the power of AI in this way, I think we have arrived at the future of medical decision making.”
Aigli Korfiati, product development manager of InSyBio states: “Years of teamwork in building sophisticated ΑΙ have now met a huge medical need. Identifying the most beneficial treatment for each chronic pain patient is now possible and straightforward. You answer the questions in our web tool and simultaneously you get the results! Our product development team worked hard towards this goal achieving to optimize the user experience of both clinicians and patients.”
Read more details on the data used for the development of this tool in our recent publication:
Gudin, J., Mavroudi, S., Korfiati, A., Theofilatos, K., Dietze, D., & Hurwitz, P. (2020). Reducing opioid prescriptions by identifying responders on topical analgesic treatment using an individualized medicine and predictive analytics approach. Journal of pain research, 13, 1255.
About InSyBio: InSyBio is an international pioneer in bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
About Clarity Science LLC: Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, Clarity aspires to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide ( www.claritysciences.org ).
For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com.
A new tool has been integrated in InSyBio Suite (InSyBio DNA-seq) which enables the fast and accurate pre-processing and analysis of DNA-sequencing data by non-bioinformatics experts with optimized pipelines. This tool includes the following functionalities:
Pre-processing of DNA-sequencing data with optimized pipelines and a user-friendly interface
Population analysis of genetics data for the identification of significant genomics biomarkers
Integration of genomic biomarkers with InSyBio Suite’s knowledge base to allow the biological interpretation of your data
Integration of genomic biomarkers with other omics biomarkers and clinical data using statistical and machine learning functionalities of InSyBio Biomarkers.
InSyBio’s CEO, Labros Digonis, stated that“Genomics is the area contributing more than 70% of the biomarkers used in clinical practice nowadays, being able to capture among other the predisposition for the development of complex diseases such as cancers and neurodegenerative diseases. Considering the feedback of our users, we have now incorporated in InSyBio Suite a tool that allows non-bioinformatics experts to analyze their genomics data, identify, validate and interpret genomic biomarkers from them without the need of dedicated computing infrastructures.”
InSyBio is offering a free, one-month license to use InSyBio Suite’s all new tools and functionalities. Request your free trial now by completing a simple form at: https://www.insybio.com/request.html .
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
In a bold approach to revolutionize a vital part of the pharmaceutical/nutraceutical industry and change the stagnant norm that is the clinical trial process, JSS Medical Research Inc. has strategically partnered with InSyBio, a leading bioinformatics company, to drive desperately needed transformation. With credit to Axios Investments Corporation for facilitating the partnership, InSyBio and JSS will closely collaborate on both pre- and post-approval studies that will be aimed at reducing time and costs for treatment approval but also ensure that they are safe and effective in the real-world setting.
As the largest Canadian-owned CRO and with an expansive presence internationally, JSS has positioned themselves as a frontrunner in the health research space and constantly pursues a superior methodology in evaluation of health care. Foreseeing the shift in industry to a precision medicine approach with increased focus on real-world-evidence, JSS will collaborate with InSyBio whose biomarker discovery and machine learning technology allows for targeted patient selection, marked risk and cost reduction which will greatly improve the probability of success in clinical trials while at the same time improving patient care in the real-world setting. Through this partnership with InSyBio, JSS has now greatly strengthened their portfolio of services by providing their clients with the tools to:
Identify and prioritize potential drug candidates and method to optimize the signal detection in clinical trials
Apply a biomarker discovery component in the clinical trials process to maximize the probability of success through more targeted patient stratification
Provide prognostic biosignatures and machine learning models for patient stratification and outcome endpoint prediction allowing for a precision medicine application of drugs and therapies
Identify the profile of responders and non-responders not covered by a specific drug, revealing new marketing opportunities for new drugs
“We at JSS look forward to enhancing the service offering we are providing to clients with the unique analytical skills and results offered by InSyBio. We believe this brings clinical research and the resulting data analysis into the modern AI age and advanced stage where better faster more accurate results in the clinical research process” stated JSS CEO & CSO, Dr. John Sampalis.
Labros Digonis, InSyBio’s CEO noted “This groundbreaking partnership with JSS will help to set an important precedent for all future clinical trials and raise the bar for measuring success. The expansion of JSS’ market reach combined with InSyBio’s trail-blazing analytics, applicable at all stages of clinical trials, empowers top pharma with optimal patient selection, minimized risk of trial failure and enables a considerably shorter time-to-market at a much lower cost.”
Anyone interested in learning more about this innovative precision medicine services package and how to use it in your pre-clinical research and/or clinical trials should contact our Director of Business Development (Ms. Mackenzie Hastings: m.hastings@insybio.com) to get more details and schedule a web presentation.
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and personalized Nutrition.
For any further detail please contact our Director of Business Development, Mackenzie Hastings, at m.hastings@insybio.com.
About JSS Medical Research Inc.: JSS Medical Research is a full‐service International Contract Research Organization (CRO) with its corporate office in Montreal, Canada and regional offices in Colombia, India and Poland.
The company offers comprehensive clinical trial management services from study design to publication of results, in Phase I‐IV trials across a broad range of therapeutic areas. With science and clinical epidemiological expertise at its core and early phase services of the highest quality adhering to industry standards, JSS Medical Research is a leader in Post‐Approval Clinical Epidemiology Studies (PACES) including Post‐Marketing Observational Studies, Health Outcomes Research (HEOR) and Health Economics. Currently, JSS Medical Research is conducting research studies in over 21 countries around the world for its clients that include the top 25 Pharmaceutical companies and Biotechnology/Device companies, worldwide.
About Axios Investments Corporation: Axios Investments Corporation is a commercial and investment firm based in Montreal, Canada that recognizes emerging opportunities in the health science an Artificial Intelligence (AI) sectors.
The new version of InSyBio Suite enables the fast and accurate analysis of omics data by non-bioinformatics experts empowered with novel techniques to explore the dark matter of the transcriptomics data. This new version:
has a new user interface to optimize the user experience of our subscribers making complex omics and multi-omics data analysis accessible to non-bioinformatics experts
allows exploration of previously unmapped reads of RNA-sequencing experiments with ready to use, efficient pipelines
minimizes the time and cost of bioinformatics analysis and provides innovative bioinformatics analysis which maximizes the chances of approval in high impact factor journals
provides more interpretable bioinformatics analysis
InSyBio Suite version 2.6 has been officially launched as of Friday November 15th 2019. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “A significant amount of reads from RNA-seq experiments (usually 5%-50%) remains unexploited because they do not match to reference transcriptomes. Our new pipeline not only enables exploiting this information with our advanced in-silico methods for the prediction and accurate classification of non-coding RNAs from these data but also reveals new potential functionalities for some of the non-coding RNAs, e.g. miRNAs which are also functioning as tRNA fragments”.
In addition to its new user interface, InSyBio Suite now offers the following unique features:
InSyBio ncRNAseq: A new non-coding RNA-seq pipeline which enables the identification and functional characterization of non-coding RNAs from the “dark matter” of RNA-sequencing data consisting of the unmapped reads.
InSyBio BioNets: A new feature is included to allow for the automatic parsing and preprocessing of GSE files from Gene Expression Omnibus Database.
InSyBio Interact: A new functional enrichment module is included and empowered by our patent-pending technology which has functionally characterized more than 90% of the human and mouse proteins and transcripts.
InSyBio’s CEO, Labros Digonis, stated that “The mission of InSyBio was always to bridge the gap of systems biology with translational research. We think that launching the new version of InSyBio Suite is a significant step in that direction as it now allows accessibility of complex bioinformatics tools and methods to molecular biologists, physicians and biotechnology researchers without requiring them to have a bioinformatics background or expensive computing infrastructures.”
InSyBio is offering a free, one-month license to use InSyBio Suite’s all new tools and functionalities. Request your free trial now by completing a simple form at: https://www.insybio.com/request.html.
The new version of InSyBio Suite will be presented by our Product Development Manager, Miss Aigli Korfiati, at the 14th annual HSCBB conference (HSCBB19 – https://sites.google.com/site/hscbb19/ which will take place at the FORTH/ICE-HT Conference Center, on December 8-10, 2019 in Patra, Greece.
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
ISyBio is showcasing as one of 7 prestigious companies during The International Accelerator’s Demo Day taking place October 22nd, 2019 at 4:30pm.
As one of the leading companies in targeted biomarker discovery, InSyBio is revolutionizing both the medical and food/nutrition research fields. We drive innovation in both clinical trials and drug discovery through our proprietary analysis approach and have been validated through numerous pilot projects and high-level publications in areas such as Cancer, Nutrition and Neurodegenerative diseases. Bellow follows an indicative list of our latest press releases:
To continue this success, InSyBio is seeking a round A of investment money ($2.0m) to:
Accelerate the commercialization of InSyBio research tools
Commercialize own identified biomarkers through diagnostic and prognostic tests for key diseases (e.g. Stroke, Brain Tumors, Nutrition etc.)
Continue R&D
Establish the lab infrastructure for biomarkers.
Further penetrate US market and reach the 500,000 target labs (pharma, research, nutrition etc.)
Demo Day Agenda:
4:30pm – 5:30pm: Networking and Refreshments
5:30pm – 7:30pm: Live Pitching
7:30pm – 8:00pm: Networking and Closing Remarks
Address: 8121 Bee Caves Rd. Austin, TX. 78747
If you are interested in attending to this event please RSVP to our Director of Business Development, Mackenzie Hastings, no later than October 18th at m.hastings@insybio.com
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
About International Accelerator: The International Accelerator is the only U.S. accelerator focused solely on investing in companies with non-U.S. citizen founders. IA provides access to seed funding, quality mentors, and services foreign-born entrepreneurs need to scale up their businesses in the United States. The International Accelerator is more than an accelerator program. It is a trusted co-founder for stateside ventures and dedicated to helping non-U.S. citizen entrepreneurs set up their U.S. company, give it an “American look and feel,” and lay a sturdy foundation to build a global business. The experienced team leverages years of international business, design, and entrepreneurial expertise, as well as access to industry experts, active investors and potential customers. At IA, the goal is to bring startups in and send them out with impressive products and the capability to stand on their own feet. Being entrepreneurs themselves, they clearly know the hardships and worries of the startup process. Apart from money, IA is always available to give the help customized for the founder, so they can focus on their product and developing their vision for the company.
In a close collaboration with a prestigious Austin, TX medical center, InSyBio applied its proprietary technology to identify targeted biomarkers to provide an unbiased, non-interventive diagnostic method for Stroke. This is incredibly important when making clinical decisions in such a time-sensitive situation as stroke, where blood biomarkers could aid in faster diagnosis and treatment. Classifying true stroke from stroke-mimic usually requires multiple tests and imaging whereas blood biomarkers’ use could considerably expedite this process and save not only precious time, but possible brain function due to faster action.
To further elaborate on the importance, Dr. Max Shpak (Center for Systems and Synthetic Biology, University of Texas at Austin) noted: “The paper by K. Theofilatos et al developed as a collaboration between the staff scientists at InSyBio and the research group at this medical center. At the time, a primary focus of the medical center’s research arm was on the clinical and biomedical aspects of stroke and other neurological conditions. InSyBio’s network-based approach to characterizing gene expression patterns provides a novel means of understanding some of the physiological sequelae associated with acute ischemic stroke events, in particular the genetic pathways in nervous, immune, and circulatory system cells that are activated or suppressed in response to stroke. Network models provide researchers with a potentially powerful tool for identifying the most functionally significant genes in these pathways. By focusing on patterns of gene co-expression and interactions among sets of genes, such network-based methods provide a more intuitive and informative means of analysis than standard methods that only consider the changes in expression levels of individual genes. It is hoped that this research will eventually provide the foundation for identifying molecular biomarkers for quantifying the magnitude of stroke effects and patient prognoses, as well as for helping to determine possible treatment options.”
Through the use of predictive analytics and network modeling, InSyBio uncovered a signature of 6 genes (ID3: inhibitor of DNA binding 3, HLH protein, MBTPS1: Membrane-bound transcription factor site-1 protease, NOG: Noggin, SFXN2: sideroflexin 2, BMX: BMX non-receptor tyrosine kinase, and SLC22A1: solute carrier family 22 member 1) that had significantly higher accuracy (89.6%) in differentiating between stroke and stroke-mimic patients and of which advanced our understanding of the physiological changes the body undergoes following a stroke. In addition to being the smallest revealed gene set to date, this biosignature is also capable of the highest diagnostic accuracy compared to the current solutions which were tested in the study. This important research is titled: “Discovery of stroke-related blood biomarkers from gene expression network models” and has now been published (link below) in one of the top genomic journals, BMC Medical Genomics.
InSyBio’s CSO, Dr. Seferina Mavroudi commented on this significance saying: “This discovery marks an important milestone in the improved diagnosis of stroke. Not only does the identified biosignature significantly increase diagnostic accuracy but it is also a small, highly targeted gene set which is incredibly important for clinical relevancy as well as the feasibility of creating a diagnostic test to be used in practice.”
About InSyBio: InSyBio is an international pioneer bioinformatics company that is revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .
In conjunction with a prestigious team of researchers and industry, InSyBio has been awarded funding under the Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) for precision nutrition. Benefiting industry and academia worldwide, the team will work to design an intelligent “virtual tongue” (VIRTUOUS) capable of taste prediction. Through the integration of drug discovery techniques, machine learning classifiers, algorithms for big data, cloud computing, and experimental data, a far greater understanding of the mechanisms behind taste profiles and the resulting sensation will be enabled.
Over the next 4 years, InSyBio will work dynamically with the other entities through the integration and tailoring of some of its already efficient bioinformatics tools, particularly InSyBio Interact, a tool able to predict a confidence score for protein pairs, extract mechanistic information and visualize both protein complexes and overall networks. The InSyBio BioNets tool will also be utilized by the VIRTUOUS team to provide a set of capabilities for the construction, preprocessing, meta-analysis, and visualization of biological networks.
Dr. Marco Agostino Deriu, coordinator of the project stated: “The VIRTUOUS Project challenges the dream of building an intelligent machine able to decrypt a sensation by modelling the biophysical architecture of our body. Taste is a complex emergent property based on molecular interactions between taste cell receptors and chemicals contained in food. This information is elaborated by our body by a complex multiscale and multiphysics network of proteins and cells which results in a signal, instantaneously elaborated by our brain, as a piano chord. The VIRTUOUS Consortium as a whole covers all required competences for this ambitious challenge, starting from molecular and multiscale modelling techniques, to artificial intelligence algorithms; experimental facilities to analyze natural product typical of the Mediterranean diet such as wine and oil. In this context, the excellent InSyBio expertise and technologies are a crucial element of this harmonized VIRTUOUS crew. Their expertise in bioinformatics and in mapping protein-protein and cell-cell networks will provide the necessary link between molecular level and tissue level phenomena.”
Labros Digonis, CEO of InSyBio, commented saying: “This sophisticated collaboration not only furthers our scientific understanding of food but also carries major market implications for nutrition, agriculture and beyond. These linked industries are required to constantly stay ahead of the curve and meet the needs of a growing population and InSyBio is aiding this effort through intelligent innovation and pioneering analysis tools.”
About RISE: RISE promotes international and cross-sector collaboration through exchanging research and innovation staff as well as sharing knowledge and ideas between research to market (and vice-versa). In the context of this project, the joint exchange program will involve 9 participants from 4 countries: Italy, Greece, Spain and Switzerland. Participants are both from academic (4 beneficiaries) and non-academic (5 beneficiaries) sectors. The balance between academy and industry and the interdisciplinary nature of the Consortium will grant a uniquely stimulating environment for all researchers involved in the project and the knowledge share will act as a spring-board for continued collaboration.
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
For any further detail contact our Director for Business Development, Mackenzie Hastings, at m.hastings@insybio.com .
In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science and the OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) to utilize advanced machine learning methods to not only predict patient response to treatment but also to stratify chronic pain patients into individuals who will benefit from topical analgesics treatment and those who will not in order to personalize treatment for optimal therapeutic results. InSyBio showed that its analysis application can predict, with high accuracy (AUC 73.8-87.2%), patient response, allowing for a first-of-its-kind precision medicine approach to treating chronic pain.
Peter Hurwitz, President of Clarity Science states: “The OPERA Study showed that there are alternative pain management treatment options available for healthcare professionals to help address a patient’s pain. These options may lead to a reduced focus on Opioid prescribing and other oral analgesics that have side effects and have a significant impact on patient care and outcomes. Collaborating with InSyBio allowed us to identify, using predictive analytics, patients who are most likely to benefit from these alternative forms of treatment without having them trial the medication first, leading to faster patient response, reduced risk of treatment failure, improved patient outcomes, and a better Quality of Life. Incorporating this methodology across other health conditions will have an immense impact on global patient health and will change current strategies and approaches to healthcare treatment.”
As the opioid use epidemic reaches an all-time high, an option for a less addictive substitute to existing pain treatments has never been more needed. Often Opioids are over-utilized due to their established ability in treating chronic pain and a lack of a proper therapeutic alternative with comparable efficacy. However, Topical agents have the potential to provide analgesic effects without the risk of abuse, misuse, and addiction or many of the systemic adverse events associated with oral analgesics. Through the use of these topical agents, in combination with InSyBio’s superior machine learning tools, a very real option to addictive oral pain medication is enabled.
Labros Digonis, CEO of InSyBio states: “Understanding which patients could benefit from an alternative prescription not only lowers their risk of addiction but also has much larger implications on a national level through the lowering of opioid abuse and related negative consequences. The answer to this epidemic lies in an improved understanding of best treatment options and InSyBio is tackling this incredible feat by acknowledging individual variability, predicting response and stratifying patients into ideal therapeutic groups. This precision pain therapy ability is a breakthrough for the industry!”
This research has been recently presented by InSyBio CSO, Dr. Mavroudi, at the 10th International conference on Information, Intelligence, Systems and Applications (IISA 2019 – http://iisa2019.upatras.gr/).
About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
About Clarity Science LLC: Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, we aspire to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide (www.claritysciences.com).
For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .
InSyBio has been recently awarded for its superior performance in the context of the Ignite Ideas program (https://igniteideas.gr/en/) which was organised by Nestle Hellas.
InSyBio has participated in this program, with its revolutionary idea of personalizing the coffee blend and type selection combining input from a saliva test and responses to questionnaires in order to maximize taste satisfaction as well as other metrics such as quality of sleep and athletic performance. This personalization is empowered with InSyBio’s proprietary biomarker discovery and predictive analytics technologies.
The whole program lasted approximately 6 months and it consisted of three intense phases including extended mentoring from experts from Nestle Hellas and the Athens Center for Entepreneurship and Innovation. During this project we had the chance to optimize the business plan for the personalized coffee selection services we provide and design a first pilot project with Nestle Hellas.
On the 23rd of May, our CEO Labros Digonis, presented our project in front of Nestle Hellas top executives together with the other 5 awarded teams (Coffeco, foodakai, bio2chp, Bespot, shopmind). Within the next 6 months our R&D team will be closely working with Nestle Hellas for implementing the pilot project that has been designed in the context of this program. The outcome of this project will be a personalized coffee selection system which will allow for the first time coffee consumers to select the coffee blend and preparation type that fit their genome and their demographic and lifestyle characteristics in order to maximize taste satisfaction.
About Ignite Ideas: “Ignite Ideas” is a Nestlé Hellas initiative aiming to support new ventures (startups) with similar business interests. The initiative is co-organised by the Athens Center for Entrepreneurship and Innovation (ACEin), the incubation center of the Athens University of Economics and Business. The program aims at developing a (virtual) accelerator of innovative ideas by equipping the participating startups with knowledge, skills, tools and the confidence required to further develop their ideas.
Innovation has been at the heart of Nestlé Group since its beginning. The inventions of Farine Lactée, the first food for infants, by Henri Nestlé in 1867, the “champagne of waters” or the Perrier water that we all know by Sir John Harmsworth in 1903, Nescafé instant coffee by a team of experts in 1929 and Nespresso by Eric Favre, a Nestlé employee back in 1975, are just some of the milestones that prove that behind every bright idea there is an equally bright mind. Today, Nestlé Group steadily invests in Research and Development, nutrition science and passion for quality. Consequently, Nestlé has the world’s largest private food and nutrition research organization, involving about 5000 people located in more than 30 R&D facilities worldwide.
Recognizing the significant presence of innovative ideas in the new Greek entrepreneurship, Nestlé Hellas through its “Ignite Ideas” program is aiming to locate the ideas that have potential for expansion and support them in order to contribute in the productive reconstruction of the country.
About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .
